![](https://investorshub.advfn.com/uicon/367184.png?cb=1553590500)
Monday, September 20, 2021 7:22:29 AM
Source: PR Newswire (US)
NAPLES, Fla., Sept. 20, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform for the mind and body using psychedelics and cannabinoids, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences:
Maxim's Advances in Mental Health Virtual Conference
Wednesday, September 22nd at 10:00 a.m. ET
Panel titled: Next Gen Psychedelics: Novel Chemical Entities
To attend, register here
Benzinga's Healthcare Small Cap Virtual Conference
Thursday, September 30th at 3:40 p.m. ET
To attend, register here
For more information about the conferences, or to schedule a one-on-one meeting with Enveric's management, please contact your appropriate representative directly, or send an email to Maxim at jthompson@maximgrp.com, Benzinga at VIPevents@benzinga.com, or KCSA Strategic Communications at EnvericBio@kcsa.com.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.
Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com
Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 212.896.1204
ckasunich@kcsa.com / rcona@kcsa.com
Cision View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-september-2021-301380168.html
SOURCE Enveric Biosciences
Copyright 2021 PR Newswire
Recent ENVB News
- Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate • Business Wire • 06/25/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 10:58:26 PM
- Enveric Biosciences to Participate in BIO International Convention 2024 • Business Wire • 05/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 09:25:22 PM
- Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results • Business Wire • 05/15/2024 10:00:00 AM
- Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders • Business Wire • 05/14/2024 12:00:00 PM
- Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids • Business Wire • 05/08/2024 11:00:00 AM
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 • Business Wire • 03/26/2024 11:00:00 AM
- Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease • Business Wire • 03/19/2024 11:00:00 AM
- Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets • Business Wire • 03/12/2024 11:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/11/2024 04:35:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:00:24 PM
- Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds • Business Wire • 02/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:53:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:47:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:42:03 PM
- Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property • Business Wire • 02/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 01:05:30 PM
- Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders • Business Wire • 02/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:36:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 01:05:27 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM